# DESCRIPTION

## CONTINUING APPLICATION DATA

- claim benefit of prior applications

## BACKGROUND

- motivate ASD diagnosis

## SUMMARY OF THE INVENTION

- introduce method for identifying metabolomic signature for autism
- assay biosamples from autistic and non-autistic subjects by GCMS
- identify differentially produced small molecule metabolites by GCMS
- assay biosamples by untargeted LC/HRMS methodologies
- identify differentially produced small molecule metabolites by LC/HRMS
- combine identified metabolites to form training set
- select subset of metabolites with statistically significant abundance difference
- describe variations of method using multiple methodologies
- specify characteristics of small molecule metabolites and biosamples
- provide examples of metabolomic signature for autism
- define metabolomic signature for autism
- list metabolites included in signature
- describe methods for determining metabolomic signature
- specify biosample sources
- describe statistical analysis for assessing risk of autism
- provide examples of metabolomic signatures for autism
- describe methods for assessing risk of autism
- specify metabolites indicative of high functioning autism (HFA) and/or low functioning autism (LFA)
- describe methods for determining ratio of small molecule metabolites
- describe combination assessment of relative abundance of small molecule metabolites
- specify biosample types
- describe methods for assessing risk of autism in subjects less than two years of age
- describe methods for assessing risk of autism in phenotypic subpopulations
- define terms used in the specification
- describe use of "and/or" in the specification
- describe use of "preferred" and "preferably" in the specification
- describe use of "comprises" and variations in the specification
- describe use of "a", "an", "the", and "at least one" in the specification
- describe recitation of numerical ranges by endpoints
- describe order of discrete steps in methods
- describe use of examples in the specification
- provide summary of the present invention
- provide guidance on interpreting the specification

## DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

- introduce metabolomics-based approach for identifying metabolic biomarkers of autism spectrum disorder (ASD)
- describe multiple high resolution mass spectrometry-based techniques for analyzing samples
- explain use of gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-high resolution mass spectrometry (LC-HR
- describe tandem mass spectrometry (MS-MS) methods for structural confirmation of metabolites
- outline data analysis using univariate, multivariate, and machine learning methods
- define training set and test set in context of statistical models
- explain quantification of data for one or more metabolites
- describe comparison of quantifying data to reference samples
- define metabolite, cellular metabolite, feature, biomarker, and metabolic signature
- outline methods for identifying metabolites in biofluids of individuals with autism
- describe blood test for diagnosis of ASD
- explain identification of metabolic biomarkers by unique molecular mass and consistency
- outline steps for identifying metabolomic signature characteristic for autism
- describe assaying biosamples by multiple methodologies
- explain combining and selecting small molecule metabolites to form a training set
- summarize method for identifying metabolomic signature for autism in a human
- describe metabolomic signature for autism
- identify training set of small molecule metabolites
- select subset of metabolites with statistically significant abundance difference
- describe alternative spectrometry methods for metabolite detection
- describe methods for identifying metabolomic signature
- provide examples of metabolic signatures of autism
- describe ranges of metabolites in metabolic signatures
- provide examples of metabolites in Table 5
- provide examples of metabolites in Table 9
- provide examples of metabolites in FIG. 13
- describe quantification methods for metabolites
- describe GCMS quantification method
- describe C8pos, C8neg, HILICpos, and HILICneg quantification methods
- reference quantification methodologies in tables
- confirm chemical identity
- demonstrate metabolic signature
- quantify abundance ratio
- relate abundance ratio to autism
- describe physical separation methods
- describe non-physical separation methods
- assay biosample for metabolites
- quantify metabolites
- relate metabolite abundance to autism
- specify number of metabolites
- specify range of metabolites
- describe method of assessing autism risk
- quantify metabolites in Table 6
- relate metabolite abundance to autism risk
- specify number of metabolites in Table 5
- quantify metabolites in Table 5
- relate metabolite abundance to autism risk
- specify number of metabolites in Table 9
- define autism diagnosis method
- describe biosample sources
- detail biosample processing
- outline metabolite extraction procedures
- introduce statistical analysis methods
- explain sensitivity and specificity measures
- discuss accuracy and precision
- define predictability
- claim autism diagnosis method with varying accuracy
- claim autism diagnosis method with varying sensitivity
- claim autism diagnosis method with varying specificity
- describe average abundance ratio determination
- detail fold change ratio calculation
- introduce ratio of signature metabolites
- discuss additional markers of autism
- outline kit for identifying metabolites associated with ASD
- describe kit components
- detail instructions for kit use
- provide example of kit application
- discuss therapeutic intervention
- conclude with invention illustration

### EXAMPLES

- motivate ASD diagnosis
- introduce ASD complexity
- describe ASD genetic studies
- discuss ASD metabolomic studies
- introduce HRMS advantages
- describe orthogonal chromatographic approach
- outline study objectives
- describe subject recruitment
- outline subject inclusion criteria
- describe sample collection and storage
- outline sample preparation for LC-MS
- describe LC-HRMS methods
- describe GC-MS methods
- outline metabolite identification
- describe metabolite structure confirmation
- introduce metabolite analysis
- describe LC-HRMS-MS methods
- outline data analysis workflow
- preprocess LC-HRMS data
- filter features by abundance and noise
- normalize feature abundance values
- split data into training and validation sets
- perform univariate filtering of mass features
- develop classification models using PLS-DA and SVM
- evaluate model performance using ROC analysis
- identify minimum feature set for classification
- annotate features with putative chemical structures
- present results of metabolite analysis
- validate model performance using independent test set
- present examples of metabolomic approach to identify biomarkers for autism spectrum disorder (ASD)
- discuss untargeted metabolomic approach to identify potential ASD biomarkers
- describe cross-validation training sets
- discuss identification of metabolites associated with ASD
- motivate mitochondrial dysfunction in ASD
- discuss potential relationship between gut microbiome and ASD
- identify previously unidentified metabolic alterations in ASD
- discuss conclusions of metabolomic approach
- introduce additional confirmed metabolites
- describe sample preparation and mass spectrometry
- discuss comparison of metabolic features between ASD and non-ASD individuals
- introduce metabolic signatures for high functioning autism and low functioning autism
- describe model accuracy, sensitivity, and specificity
- discuss overlap of biometabolic signatures between HFA and LFA populations
- present putative identifications of metabolic features
- discuss abundance of biometabolic features in autistic and typical subjects
- introduce additional cohorts for metabolomic analysis
- describe non-targeted metabolomic analysis approach
- discuss mapping of metabolites to metabolic pathways
- motivate development of clinical diagnostic kit
- discuss incorporation of patents, patent applications, and publications by reference
- provide disclaimer for inconsistencies in disclosure
- provide general disclaimer for the invention

